Rani Therapeutics has developed a disruptive technology to enable orally administered biologics and drugs. The RaniPill® is a simple-to-swallow robotic capsule that delivers biologics orally, offering injectable-like bioavailability without a needle.
Rani's technology enables oral delivery of hundreds of approved biologic drugs that currently lack oral formulations, providing an opportunity to expand markets in immunology, endocrinology, oncology, and other key therapeutic areas.
Watch how the capsule travels from swallow to systemic absorption — engineered for protection and precise delivery of biologics.
The RaniPill® platform has demonstrated clinical proof of concept across 19 different biologic molecules, including peptides, proteins, and monoclonal antibodies, in 146 patients with 233 administrations, achieving bioavailability comparable to subcutaneous injections with no serious adverse events. 100% of patients in clinical trials have successfully swallowed RaniPill®.
Explore our pipeline →The Rani platform is capable of orally delivering any payload, including proteins, peptides, and antibodies.